Skip to main content
. Author manuscript; available in PMC: 2023 Dec 21.
Published in final edited form as: Cell Syst. 2022 Dec 2;13(12):1048–1064.e7. doi: 10.1016/j.cels.2022.11.003
S.No TCGA Study Name N (tumor) N (normal)
1 ACC Adrenocortical carcinoma 77 128
2 BLCA Bladder Urothelial Carcinoma 404 28
3 BRCA Breast invasive carcinoma 1085 291
4 CESC Cervical squamous cell carcinoma & endocervical adenocarcinoma 305 13
5 CHOL Cholangiocarcinoma 36 9
6 COAD Colon adenocarcinoma 275 349
7 DLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma 47 337
8 ESCA Esophageal carcinoma 182 286
9 GBM Glioblastoma multiforme 163 207
10 HNSC Head and Neck squamous cell carcinoma 519 44
11 KICH Kidney Chromophobe 66 53
12 KIRC Kidney renal clear cell carcinoma 523 100
13 KIRP Kidney renal papillary cell carcinoma 286 60
14 LAML Acute Myeloid Leukemia 173 70
15 LGG Brain Lower Grade Glioma 518 207
16 LIHC Liver hepatocellular carcinoma 369 160
17 LUAD Lung adenocarcinoma 483 347
18 LUSC Lung squamous cell carcinoma 486 338
19 MESO Mesothelioma 87 426
20 OV Ovarian serous cystadenocarcinoma 88 179
21 PAAD Pancreatic adenocarcinoma 179 171
22 PCPG Pheochromocytoma and Paraganglioma 182 3
23 PRAD Prostate adenocarcinoma 492 152
24 READ Rectum adenocarcinoma 92 318
25 SARC Sarcoma 262 2
26 SKCM Skin Cutaneous Melanoma 461 558
27 STAD Stomach adenocarcinoma 408 211
28 TGCT Testicular Germ Cell Tumors 137 165
29 THCA Thyroid carcinoma 512 337
30 THYM Thymoma 118 339
31 UCEC Uterine Corpus Endometrial Carcinoma 174 91
32 UCS Uterine Carcinosarcoma 57 78
33 UVM Uveal Melanoma 79 0